Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
As the world is beginning to understand, SARS-CoV-2 poses several unique challenges. Asymptomatic and infected individuals are highly contagious and present unprecedented viral transmissibility. As countries and markets try to fully understand the economic impact of the pandemic, the value of a rapid diagnostic test for a rapidly spreading virus has never been more clearly demonstrated. The IATA projects that worldwide, the airline industry alone will see 2020 full year passenger revenues plummet by $252 billion, or 44% below 2019’s figure.
In the absence of a vaccine or a treatment for SARS-CoV-2, the only strategy against the spread of the novel coronavirus is to “detect and isolate.” While the number of new cases continues to rise throughout the world, there is a clear escalation of technologies and products to detect SARS-CoV-2. Given the nature and scale of the pandemic, we expect diagnostic trends such as access to point of care, connected systems, and innovative sample collection techniques to accelerate the market landscape.
